Related Experiment Video

Updated: Nov 1, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

Catherine Dunn1, Lucy Gately1, Peter Gibbs1,2

  • 1Personalised Medicine Division, Walter and Eliza Hall Research Institute, Melbourne, Victoria, Australia.

JAMA Oncology
|June 17, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K

Related Experiment Videos

Last Updated: Nov 1, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

95.0K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
95.0K

Articles linked to this work by shared authors, journal, and citation graph.

Impact of Immunotherapy Prescribing Restrictions on Time to Systemic Therapy and Outcomes in Metastatic Clear Cell Renal Carcinoma in Australia.

Asia-Pacific journal of clinical oncology·2026

Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay.

The Journal of molecular diagnostics : JMD·2026

Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009-2024) to Guide Treatment Planning.

The Medical journal of Australia·2026

Real-world outcomes in patients with hormone receptor positive, human epidermal growth factor receptor 2 receptor-negative advanced breast cancer and visceral metastases at baseline - advanced hormone receptor positive breast cancer registry in Australia.

Internal medicine journal·2026

Artificial Intelligence-Assisted Risk Stratification in Stage II Colorectal Cancer: Multi-Institutional Validation of Semantically Enhanced Deep Learning.

Gastroenterology·2026

Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns.

Journal of neuro-oncology·2026

Management of Soft Tissue and Visceral Leiomyosarcomas.

JAMA oncology·2026

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial.

JAMA oncology·2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

JAMA oncology·2026

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

JAMA oncology·2026

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review.

JAMA oncology·2026

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients.

JAMA oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us